Increases in the availability of prescribed opioids in a Canadian setting

Drug and Alcohol Dependence

Volumn 126, Issue 1-2, 2012, Pages 7-12

  Nosyk, B ^a   Marshall, B D L ^a,b   Fischer, B ^c,d   Montaner, J S G ^a   Wood, E ^a   Kerr, T ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b Department of Medicine   (United States)

^c SIMON FRASER UNIVERSITY   (Canada)

^d CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

Author keywords

Availability; Hydromorphone; Illicit drugs; Methadone; Oxycodone; Prescribed opioids

Indexed keywords

ACETYLSALICYLIC ACID; CANNABIS; CODEINE; HYDROMORPHONE; METHADONE; METHAMPHETAMINE; MORPHINE; OXYCODONE; PARACETAMOL;

ADULT; ARTICLE; CANADA; DRUG MISUSE; DRUG TRAFFIC; FEMALE; HUMAN; INAPPROPRIATE PRESCRIBING; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PUBLIC HEALTH PROBLEM; TREND STUDY;

ADULT; ANALGESICS, OPIOID; BRITISH COLUMBIA; CANADA; COHORT STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OPIOID-RELATED DISORDERS; PRESCRIPTION DRUGS; PROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84867892812     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2012.03.010     Document Type: Article

References (39)

1. Brands B., Blake J., Sproule B., Gourlay D., Busto U. Prescription opioid abuse in patients presenting for methadone maintenance treatment. Drug Alcohol Depend. 2004, 73:199-207.
2. Bruneau J., Roy E., Arruda N., Zang G., Jutras-Aswad D. The rising prevalence of prescription opioid injection and its association with hepatitis C incidence among street-drug users. Addiction 2012, 10.1111/j.1360-0443.2012.03803.x.
3. Caulkins J.P. Price and purity analysis for illicit drugs: data and conceptual issues. Drug Alcohol Depend. 2007, 90(Suppl. 1):S61-S68.
4. Chou R., Fanciullo G.J., Fine P.G., American Pain Society-American Academy of Pain Medicine Opioids Guidelines Panel Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J. Pain 2009, 10:113-130.
5. College of Pharmacists of British Columbia, 2011. Guidelines for Addressing Pharmacy Robbery in BC. Accessed November 1, 2011. http://www.bcpharmacists.org/news_events/news/news136.php.
6. Davis W.R., Johnson B.D. Prescription opioid use, misuse, and diversion among street drug users in New York City. Drug Alcohol Depend. 2008, 92:267-276.
7. Dhalla I.A., Mamdani M.M., Gomes T., Juurlink D.N. Clustering of opioid prescribing and opioid-related mortality among family physicians in Ontario. Can. Fam. Physician 2011, 57:e92-e96.
8. U.S. Food and Drug Administration. FDA NEWS RELEASE: FDA Approves New Formulation for OxyContin. Accessed March 22, 2012. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm207480.htm.
9. Fischer B., Rehm J., Brissette S., Brochu S., Bruneau J., El-Guebaly N., Noël L., Tyndall M., Wild C., Mun P., Baliunas D. Illicit opioid use in Canada: comparing social, health, and drug use characteristics of untreated users in five cities (OPICAN study). J. Urban Health 2005, 82:250-266.
10. Fischer B., Jones W., Krahn M., Rehm J. Differences and over-time changes in levels of prescription opioid analgesic dispensing from retail pharmacies in Canada, 2005-2010. Pharmacoepidemiol. Drug Saf. 2011, 20:1269-1277.
11. Gang violence in B.C. linked to Mexico Drug Wars. Accessed November 1, 2011. http://www.ctvbc.ctv.ca/servlet/an/local/CTVNews/20090304/bc_mexico_drugs_090304/20090304/?hub=BritishColumbiaHome.
12. Gomes T., Mamdani M.M., Dhalla I.A., Paterson J.M., Juurlink D.N. Opioid dose and drug-related mortality in patients with nonmalignant pain. Arch. Intern. Med. 2011, 171:686-691.
13. Gomes T., Juurlink D.N., Dhalla I.A., Mailis-Gagnon A., Paterson J.M., Mamdani M.M. Trends in opioid use and dosing among socio-economically disadvantaged patients. Open Med. 2011, 5:e13-e22.
14. Harris K.A., Arnsten J.H., Joseph H., Hecht J., Marion I., Juliana P., Gourevitch M.N. A 5-year evaluation of a methadone medical maintenance program. J. Subst. Abuse Treat. 2006, 31:433-438.
15. Kreek M.J., Borg L., Ducat E., Ray B. Pharmacotherapy in the treatment of addiction: methadone. J. Addict. Dis. 2010, 29:200-216.
16. Kurdyak P., Gomes T., Yao Z., Mamdani M.M., Hellings C., Fischer B., Rehm J., Bayoumi A.M., Juurlink D.N. Use of other opioids during methadone therapy: a population-based study. Addiction 2011, 107:776-780.
17. Marshall B.D., Milloy M.J., Wood E., Montaner J.S., Kerr T. Reduction in overdose mortality after the opening of North America's first medically supervised safer injecting facility: a retrospective population-based study. Lancet 2011, 377:1429-1437.
18. National Centre for Injury Prevention and Control. Centers for Disease Control. Centers for Disease Control and Prevention. Unintentional drug poisoning in the United States [July 2010]. Accessed November 1st, 2011. http://www.cdc.gov/HomeandRecreationalSafety/Poisoning/index.html.
19. Nosyk B., Marsh D.C., Sun H., Schechter M.T., Anis A.H. Trends in methadone maintenance treatment participation, retention and compliance to dosing guidelines in British Columbia, Canada: 1996-2006. J. Subst. Abuse Treat. 2010, 39:22-31.
20. Popova S., Patra J., Mohapatra S., Fischer B., Rehm J. How many people in Canada use prescription opioids non-medically in general and street drug using populations?. Can. J. Public Health 2009, 100:104-108.
21. Rosenblum A., Parrino M., Schnoll S.H., Fong C., Maxwell C., Cleland C.M., Magura S., Haddox J.D. Prescription opioid abuse among enrollees into methadone maintenance treatment. Drug Alcohol Depend. 2007, 90:64-71.
22. Roy E., Arruda N., Bourgois P. The growing popularity of prescription opioid injection in downtown Montréal: new challenges for harm reduction. Subst. Use Misuse 2011, 46:1142-1150.
23. Ruel J.-M., Hickey C.P. Diversion of methadone: what are the risks?. B. C. Med. J. 1993, 35:420-421.
24. Salsitz E.A., Joseph H., Frank B., Perez J., Richman B.L., Salomon N., Kalin M.F., Novick D.M. Methadone medical maintenance (MMM): treating chronic opioid dependence in private medical practice-a summary report (1983-1998). Mt. Sinai J. Med. 2000, 67:388-397.
25. Statistics Canada. Accessed March 22, 2012. http://www.statcan.gc.ca/pub/85-225-x/2010000/tablesectlist-listetableauxsect-eng.htm.
26. Strathdee S.A., Palepu A., Cornelisse P.G., Yip B., O'Shaughnessy M.V., Montaner J.S., Schechter M.T., Hogg R.S. Barriers to use of free antiretroviral therapy in injection drug users. JAMA 1998, 280:547-549.
27. Strathdee S.A., Patrick D.M., Currie S.L., Cornelisse P.G., Rekart M.L., Montaner J.S., Schechter M.T., O'Shaughnessy M.V. Needle exchange is not enough: lessons from the Vancouver injecting drug use study. AIDS 1997, 11:F59-F65.
28. Substance Abuse and Mental Health Service Administration - Center for Behavioural Health Statistics and Quality, 2011. [Accessed January 31, 2012]. http://wwwdasis.samhsa.gov/webt/tedsweb/tab_year.choose_year_web_table?t_state=US.
29. Tyndall M.W., Currie S., Spittal P., Li K., Wood E., O'Shaughnessy M.V., Schechter M.T. Intensive injection cocaine use as the primary risk factor in the Vancouver HIV-1 epidemic. AIDS 2003, 17:887-893.
30. Sajan A., Corneil T., Grzybowski S. The street value of prescription drugs. CMAJ 1998, 159:139-142.
31. US Department of Health and Human Services, 2011a. Centers for Disease Control and Prevention: Morbidity and Mortality Weekly Report. Vital Signs: Overdoses of Prescription Opioid Pain Relievers - United States, 1999-2008. November 1, 2011. Volume 60. [Accessed November, 2011]. http://responsibleopioidprescribing.org/index_12_3736347817.pdf.
32. Volkow N.D., McLellan T.A. Curtailing diversion and abuse of opioid analgesics without jeopardizing pain treatment. JAMA 2011, 305:1346-1347.
33. Volkow N.D., McLellan T.A., Cotto J.H., Karithanom M., Weiss S.R. Characteristics of opioid prescriptions in 2009. JAMA 2011, 305:1299-1301.
34. Wood E., Tyndall M.W., Spittal P.M., Li K., Anis A.H., Hogg R.S., Montaner J.S., O'Shaughnessy M.V., Schechter M.T. Impact of supply-side policies for control of illicit drugs in the face of the AIDS and overdose epidemics: investigation of a massive heroin seizure. CMAJ 2003, 168:165-169.
35. Wood E., Spittal P.M., Small W., Kerr T., Li K., Hogg R.S., Tyndall M.W., Montaner J.S., Schechter M.T. Displacement of Canada's largest public illicit drug market in response to a police crackdown. CMAJ 2004, 170:1551-1556.
36. Wood E., Stoltz J.A., Li K., Montaner J.S., Kerr T. Changes in Canadian heroin supply coinciding with the Australian heroin shortage. Addiction 2006, 101:689-695.
37. Wood E., Kerr T. What do you do when you hit rock bottom? Responding to drugs in the city of Vancouver. Int. J. Drug Policy 2006, 17:55-60.
38. Wood E., Stoltz J.A., Montaner J.S., Kerr T. Evaluating methamphetamine use and risks of injection initiation among street youth: the ARYS study. Harm Reduct. J. 2006, 3:18.
39. Wood E., Kerr T., Marshall B.D.L., Li K., Zhang R., Hogg R.S., Harrigan P.R., Montaner J.S.G. Longitudinal community plasma HIV-1-RNA concentrations and incidence of HIV-1 among injecting drug users: a prospective cohort study. BMJ 2009, 338:1191-1194.